- January 24, 2020
OncoCyte Launches NSCLC Stratification Test, Looks beyond Lung Cancer
OncoCyte president and CEO Ron (Ronnie) Andrews discussed the company’s recent acquisitions and expansion of its diagnostics menu with GEN Edge . . .
- January 24, 2020
Pharma Technology Focus: treating zebras
Horizon 2020, the European Union’s research and innovation programme, is entering its final year. But how has the money been used to drive pharma developments in the region? We round up the most successful and innovative projects to emerge from scheme.
- January 24, 2020
HPV-Cancer Targeting Immunotherapy Enters Phase 1 Clinical Trial After Showing Success In Animals
This week the publishing of data on Cue Biopharma’s star immunotherapy molecule, Cue 101, revealed just how much reality there is to concept. A paper published in Clinical Cancer Research on Tuesday showed research demonstrating the ability of a biologic immunotherapy drug candidate named CUE-101 to activate tumor antigen-specific antitumor immunity.
- January 23, 2020
Krystal Biotech Names Genzyme’s Chien Chief Commercial Officer
Gene therapy developer Krystal Biotech (NASDAQ: KRYS) has appointed Jennifer Chien to the newly created role of chief commercial officer. She comes to Pittsburgh-based Krystal from the Genzyme unit of Sanofi (NYSE: SNY), where she was vice president and head of genetic diseases.
- January 23, 2020
Orasis Developing Eye Drops as Alternative to Reading Glasses
As people age, the ability of their eyes to focus on objects near to them weakens. The condition, known as presbyopia, affects more than 1.8 billion people worldwide. Though reading glasses provide a solution to the problem, Orasis Pharmaceuticals is developing a corrective eyedrop it says will provide an alternative.
- January 22, 2020
Immuneering Raises $20 Million for New Drug-Discovery Effort
Venture capitalists are betting $20 million that technology from Immuneering Corp. will enable it to develop medicines aimed at molecular targets that have long tantalized and eluded drugmakers.
- January 22, 2020
2020 Could be a Defining Year for SQZ Biotech
If 2019 was a breakthrough year for Watertown, Mass.-based SQZ Biotech, 2020 could be a defining year as the company tests is first antigen-presenting cell asset in the clinic to treat solid tumors that are HPV positive.